Scientists test Two-Pronged attack on rare gut tumors

NCT ID NCT04750954

First seen Nov 01, 2025 · Last updated Apr 16, 2026 · Updated 30 times

Summary

This early-stage trial is testing a new combination treatment for advanced neuroendocrine tumors that have spread in the digestive system. Researchers are combining an oral pill (peposertib) with a targeted radiation therapy (Lutetium-177 dotatate) to see if they work better together. The main goals are to find the safest and most effective dose and to check for early signs that the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.